NCT01217177View on ClinicalTrials.gov

A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Locally Advanced Cervical Cancer
Interventions
DRUG

everolimus

Trial Locations (2)

20230-130

Novartis Investigative Site, Rio de Janeiro

Unknown

Novartis Investigative Site, Rio de Janeiro

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY